Modulari-T Bioscience announced a research collaboration with a global top-10 pharma company to develop a novel in vivo CAR-T program targeting an undisclosed solid tumor. The Montreal-based biotech said the work will be supported through CQDM under the Quantum Leap program, signaling continued momentum for in vivo cellular engineering beyond conventional ex vivo CAR-T. In a parallel sector update, Cytomos highlighted the ongoing bottleneck in CAR-T scale-up: manufacturing variability and the lack of predictive, real-time visibility into cellular fate during production. The company framed its AuraCyt predictive cell intelligence platform as an approach to detect earlier cellular states to support more proactive process control. Together, the announcements reflect two complementary strategies in CAR-T—new biological architectures for delivery and improved industrial instrumentation to reduce yield risk and expand patient access.